Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057603 | 1.00 | CES2 (0.39) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL5983660 | 1.00 | CES2 (0.39) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL5665231 | 1.00 | CES2 (0.39) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL5179328 | 1.00 | CES2 (0.39) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL5178373 | 0.98 | CES2 (0.38) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9274885 | 0.95 | CES2 (0.36) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL28854780 | 0.94 | CES2 (0.40) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL15572971 | 0.94 | CES2 (0.40) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL3208385 | 0.93 | TSHR (0.42) | CES2GPR84PPARGPPARDPPARA | |
| Acetic Acid SCHEMBL4292824 | 0.92 | MEN1 (0.35) | CES2GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068307-A1 | DERMATOLOGICAL EMULSION AND METHOD FOR THE PREPARATION THEREOF | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-03-18 | — | — | US | claimed |
| US-20060275236-A1 | Personal skin care compositions containing anti-flammatory and anti-microbial agents | JORMAY, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-5795695-A | PHOTO-QUALITY RECORDING | XEROX CORPORATION (US) | 1998-08-18 | — | — | US | claimed |
| US-20220125935-A1 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS COMPRISING SKIN-PENETRATING NUCLEIC ACID COMPLEX AS EFFECTIVE COMPONENT | SEASUN THERAPEUTICS (KR) | 2022-04-28 | — | — | US | disclosed |
| US-20220117862-A1 | COLORATION COSMETIC COMPOSITION WITH VARIABLE-COLOR CAPSULES | KOLMAR KOREA CO., LTD. (KR) | 2022-04-21 | — | — | US | disclosed |
| EP-3878474-A1 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS COMPRISING SKIN-PENETRATING NUCLEIC ACID COMPLEX AS EFFECTIVE COMPONENT | Seasun Therapeutics (KR) | 2021-09-15 | — | — | EP | disclosed |
| WO-2020184784-A1 | COLORATION COSMETIC COMPOSITION WITH VARIABLE-COLOR CAPSULES | 한국콜마주식회사 | 2020-09-17 | — | — | WO | disclosed |
| US-20190328753-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | OCULAR RESOURCES LLC | 2019-10-31 | — | — | US | disclosed |
| US-20170260342-A1 | HIGH-RECOVERABILITY RESIN PARTICLES AND USE THEREOF | SEKISUI PLASTICS CO., LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| EP-3215114-A1 | OXIDATIVE HAIR DYE | Henkel AG & Co. KGaA (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3192815-A1 | HIGH-RECOVERABILITY RESIN PARTICLES AND USE THEREOF | Sekisui Plastics Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-6171702-B1 | Coated substrates | XEROX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0671157-B1 | Cosmetic composition comprising cationic thickener | OSAKA YUKI KAGAKU KOGYO (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0930888-A1 | PHARMACEUTICAL AND COSMETIC ANTIACNE FORMULATIONS CONTAINING PLANT EXTRACTS (KRAMERIA TRIANDRA OR MESUA FERREA) | INDENA S.p.A. (IT) | 1999-07-28 | — | — | EP | disclosed |
| US-5795695-A | PHOTO-QUALITY RECORDING | XEROX CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1998017293-A1 | PHARMACEUTICAL AND COSMETIC ANTIACNE FORMULATIONS CONTAINING PLANT EXTRACTS (KRAMERIA TRIANDRA OR MESUA FERREA) | INDENA S.P.A. (IT) | 1998-04-30 | — | — | WO | disclosed |
| US-5603926-A | CONTAINS A (METH)ACRYLIC MONOMER HAVING AN AMINO GROUP | OSAKA YUKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0671157-A1 | Cosmetic composition comprising cationic thickener | OSAKA YUKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0603405-A1 | COMPOSITION FOR TREATING ACNE VULGARIS | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1994-06-29 | — | — | EP | disclosed |
| EP-0479121-A1 | Skin treatment compositions containing beta-phosphatidyl choline derivatives | FIDIA S.p.A. (IT) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328753-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | MGLL, HSD17B1, HSD11B2 | CES2 4403/4885GPR84 2064/4885PPARG 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.